Molecular Partners Ag MOLN
NASDAQ MOLN
$4.18 -0.17 (-3.76%)
As of: Sep 10, 2026 · 9:51 AM EDT

Molecular Partners Ag (MOLN) Net Income (2020 - 2026)

Molecular Partners Ag's (MOLN) quarterly Net Income came in at -$17.2 million in Q2 2026, up 30.33% year-over-year from -$13.2 million in Q2 2025, and down 2.22% quarter-over-quarter from -$16.8 million in Q1 2026.

Analysis

Molecular Partners Ag (MOLN) Net Income (2020 - 2026) Analysis & Trends

Molecular Partners Ag (MOLN) has reported Net Income for 7 consecutive years, with -$17.2 million the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Net Income rose 30.33% year-over-year to -$17.2 million in Q2 2026; TTM through Jun 2026 was -$64.6 million, a 13.96% increase from a year earlier, with the FY2025 full-year figure at -$74.4 million, down 21.05% from the prior year.
  • Net Income was -$17.2 million for Q2 2026 at Molecular Partners Ag, down from -$16.8 million in the prior quarter.
  • Over five years, Net Income peaked at $165.8 million in Q1 2022 and troughed at -$24.6 million in Q2 2025.
  • A 5-year average of -$6.1 million and a median of -$16.3 million in 2023 frame the typical range for Net Income.
  • Across the five-year window, Net Income jumped 1005.54% in 2022 and slumped 279.18% in 2023, its largest moves.
  • Over 5 years, Net Income stood at -$18.1 million in 2022, then decreased by 23.22% to -$22.3 million in 2023, then jumped by 42.52% to -$12.8 million in 2024, then fell by 23.43% to -$15.8 million in 2025, then fell by 8.56% to -$17.2 million in 2026.
  • The last three Net Income figures came in at -$17.2 million (Q2 2026), -$16.8 million (Q1 2026), and -$15.8 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 2.38 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn -10.50 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn 1.10 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 1.30 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn 601.00 Mn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn -782.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn 164.49 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 97.50 Mn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn -290.61 Mn
10 Molecular Partners Ag 156.54 Mn 156.54 Mn - -17.16 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -17.16 Mn
Mar 31, 2026 -16.79 Mn
Dec 31, 2025 -15.81 Mn
Sep 30, 2025 -14.80 Mn
Jun 30, 2025 -24.64 Mn
Mar 31, 2025 -18.66 Mn
Dec 31, 2024 -12.81 Mn
Sep 30, 2024 -18.94 Mn
Jun 30, 2024 -16.68 Mn
Mar 31, 2024 -12.98 Mn
Dec 31, 2023 -22.29 Mn
Sep 30, 2023 -12.96 Mn
Jun 30, 2023 -17.78 Mn
Mar 31, 2023 -15.98 Mn
Dec 31, 2022 -18.09 Mn
Sep 30, 2022 -13.80 Mn
Jun 30, 2022 -4.69 Mn
Mar 31, 2022 165.80 Mn
Dec 31, 2021 -19.41 Mn
Sep 30, 2021 -13.41 Mn